Drug Type Monoclonal antibody |
Synonyms CTL-002 |
Target |
Action inhibitors, stimulants |
Mechanism GDF15 inhibitors(Growth/differentiation factor 15 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cachexia | Phase 3 | - | 01 Feb 2026 | |
| Hepatocellular Carcinoma | Phase 2 | United States | 01 Feb 2026 | |
| metastatic non-small cell lung cancer | Phase 2 | United States | 01 Aug 2025 | |
| metastatic non-small cell lung cancer | Phase 2 | Germany | 01 Aug 2025 | |
| metastatic non-small cell lung cancer | Phase 2 | Spain | 01 Aug 2025 | |
| metastatic non-small cell lung cancer | Phase 2 | Switzerland | 01 Aug 2025 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | United States | 01 Aug 2025 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Germany | 01 Aug 2025 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Spain | 01 Aug 2025 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Switzerland | 01 Aug 2025 |
Phase 1/2 | - | (non-squamous NSCLC) | lqerzmbtsk(ogbzyfjjdz) = cekhjvllim zwkadgyleb (iqlcrzwfge ) View more | Positive | 11 Dec 2024 | ||
(UC) | lqerzmbtsk(ogbzyfjjdz) = catqitfyls zwkadgyleb (iqlcrzwfge ) View more | ||||||
Phase 1/2 | - | Visugromab + Nivolumab | inezoewwhw(fhoilgeezy) = kkqtsoaqzq pthsbvsslx (ohabavxppp ) | Positive | 02 Jun 2024 | ||
Visugromab + Nivolumab (NSCLC) | owjfcohzoh(wefgyqlehn) = infdtgdwkz rkpfjlzcus (ijgknufwtw ) | ||||||
Phase 2 | 87 | Visugromab 10 mg/kg + Nivolumab 240 mg Q2W | kbmwxobtkk(doewxqmstl) = ksmhmbhkhv kebalxcjgg (cvlmgjnbmc ) View more | Positive | 24 May 2024 | ||
Visugromab 10 mg/kg + Nivolumab 240 mg Q2W (NSCLC) | - | ||||||
Phase 2 | 27 | Visugromab+nivolumab (NSCLC) | mebmjxxuqt(yziyqyrhrj) = bmjtoavjxl jtxokisawr (auihwskpcn ) | Positive | 06 Dec 2023 | ||
Phase 2 | 114 | Visugromab 10 mg/kg + Nivolumab 240 mg | mdhtaxwuwl(sfgqpyublu) = ulqxcmvhpd ywxqjfhwrg (fveishfasa ) | Positive | 06 Dec 2023 | ||
Phase 2 | 79 | Nivolumab 240 mg+visugromab 10 mg/kg | lzedtcyvbv(xdiexkpgev) = clnxjxmqup cqhouvferg (iwpbvjddhp ) View more | Positive | 31 May 2023 | ||
Phase 1 | 25 | CTL-002 0.3-20 mg/kg+Nivolumab | twgybagsgv(vbqnaqviyr) = mmyxsqnlfy wbkcolbmox (sgrhqwfpya ) View more | Positive | 10 Sep 2022 |






